Juvenile Idiopathic Arthritis

The approval of etanercept for juvenile idiopathic arthritis in 1999 heralded a new era for children with arthritis. However, despite subsequent approvals for JIA, many patients with other types of childhood arthritis remain without options.

A significant number of children with juvenile idiopathic arthritis treated prior to the treat-to-target era demonstrated persistently active disease up to 5 years later, according to data from an Italian pediatric hospital.

The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release.

WASHINGTON — Patients with juvenile idiopathic arthritis receive biologic disease-modifying antirheumatic drugs significantly sooner on public insurance vs. private, particularly if they have oligoarticular JIA, according to a speaker.

The FDA has granted rare pediatric disease designation to a type IA prodrug of dexamethasone that targets CD206+ macrophages for the treatment of systemic juvenile idiopathic arthritis flares, according to a press release from PIF Partners.

The FDA has expanded the approval of an oral liquid methotrexate solution to include children and adolescents with polyarticular juvenile idiopathic arthritis and acute lymphoblastic leukemia, according to a press release.

Intravenous golimumab yielded a durable clinical response through 116 weeks, with a stable safety profile, in polyarticular-course juvenile idiopathic arthritis, according to data published in The Journal of Rheumatology.

In this edition, drug discounts through Medicare price negotiations, opioid use has fallen 15% annually since 2014 and more.

Lower levels of S100 proteins at baseline predict better treatment response with abatacept in patients with polyarticular-course juvenile idiopathic arthritis, according to data published in Arthritis Research & Therapy.

It may be possible to forecast persistent disease activity in juvenile idiopathic arthritis using C-reactive protein-to-albumin ratio and neutrophil-to-lymphocyte ratio, according to data published in BMC Rheumatology.